MXPA06003695A - Usos terapeuticos de variantes de quimiocinas. - Google Patents
Usos terapeuticos de variantes de quimiocinas.Info
- Publication number
- MXPA06003695A MXPA06003695A MXPA06003695A MXPA06003695A MXPA06003695A MX PA06003695 A MXPA06003695 A MX PA06003695A MX PA06003695 A MXPA06003695 A MX PA06003695A MX PA06003695 A MXPA06003695 A MX PA06003695A MX PA06003695 A MXPA06003695 A MX PA06003695A
- Authority
- MX
- Mexico
- Prior art keywords
- ccl2
- seq
- polypeptide
- sequence
- chemokine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/521—Chemokines
- C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/24—Immunology or allergic disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/285—Demyelinating diseases; Multipel sclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Pathology (AREA)
- Rheumatology (AREA)
- Biotechnology (AREA)
- Toxicology (AREA)
- General Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03078308 | 2003-10-16 | ||
| PCT/EP2004/052572 WO2005037305A1 (en) | 2003-10-16 | 2004-10-18 | Therapeutic uses of chemokine variants |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA06003695A true MXPA06003695A (es) | 2006-06-20 |
Family
ID=34442986
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA06003695A MXPA06003695A (es) | 2003-10-16 | 2004-10-18 | Usos terapeuticos de variantes de quimiocinas. |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US7740833B2 (https=) |
| EP (1) | EP1673103A1 (https=) |
| JP (1) | JP2007510403A (https=) |
| KR (1) | KR20070008510A (https=) |
| CN (1) | CN1867352A (https=) |
| AR (1) | AR046594A1 (https=) |
| AU (1) | AU2004281552B2 (https=) |
| BR (1) | BRPI0415290A (https=) |
| CA (1) | CA2536082A1 (https=) |
| EA (1) | EA009414B1 (https=) |
| IL (1) | IL175020A0 (https=) |
| MX (1) | MXPA06003695A (https=) |
| NO (1) | NO20062109L (https=) |
| UA (1) | UA91820C2 (https=) |
| WO (1) | WO2005037305A1 (https=) |
| ZA (1) | ZA200601900B (https=) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2007021807A1 (en) | 2005-08-12 | 2007-02-22 | Schering Corporation | Mcp1 fusions |
| WO2007113285A2 (en) * | 2006-03-31 | 2007-10-11 | Biotherapix Molecular Medicines S.L.U. | Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors |
| US20100166733A1 (en) * | 2006-06-21 | 2010-07-01 | Zurit Levin | Mcp-1 splice variants and methods of using same |
| ES2434039T3 (es) * | 2006-07-24 | 2013-12-13 | Yeda Research And Development Co. Ltd. | Composiciones farmacéuticas que comprenden ccl2 para su uso en el tratamiento de la inflamación |
| US20080076120A1 (en) * | 2006-09-14 | 2008-03-27 | Millennium Pharmaceuticals, Inc. | Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders |
| WO2010086426A1 (en) * | 2009-01-30 | 2010-08-05 | Protaffin Biotechnologie Ag | Glycosaminoglycan-antagonising mcp-i mutants and methods of using same |
| US8524217B2 (en) | 2010-05-11 | 2013-09-03 | Merck Sharp & Dohme Corp. | MCP1-Ig fusion variants |
| US9249204B2 (en) | 2011-06-01 | 2016-02-02 | Jyant Technologies, Inc. | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| US20130330337A1 (en) * | 2011-06-01 | 2013-12-12 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| WO2012166588A2 (en) * | 2011-06-01 | 2012-12-06 | Morehouse School Of Medicine | Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof |
| ES2664836T3 (es) * | 2011-06-13 | 2018-04-23 | Tla Targeted Immunotherapies Ab | Tratamiento de esclerosis múltiple |
| US9726666B2 (en) | 2011-06-13 | 2017-08-08 | Tla Targeted Immunotherapies Ab | Diagnosing and treating inflammatory diseases |
| ES2764840T3 (es) | 2015-01-28 | 2020-06-04 | Univ Bordeaux | Uso de plerixafor para tratar y/o prevenir exacerbaciones agudas de la enfermedad pulmonar obstructiva crónica |
| CN107207603A (zh) * | 2015-02-03 | 2017-09-26 | 吉安特科技股份有限公司 | 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途 |
| WO2018106945A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| EP3554541B1 (en) | 2016-12-14 | 2023-06-07 | Biora Therapeutics, Inc. | Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor |
| KR102066149B1 (ko) * | 2018-08-17 | 2020-01-14 | 고려대학교 산학협력단 | Ccl2를 유효성분으로 포함하는 임신촉진용 조성물 |
| EP3883635A1 (en) | 2018-11-19 | 2021-09-29 | Progenity, Inc. | Methods and devices for treating a disease with biotherapeutics |
| CN115666704B (zh) | 2019-12-13 | 2025-09-26 | 比特比德科有限责任公司 | 用于将治疗剂递送至胃肠道的可摄取装置 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH09507211A (ja) * | 1993-09-14 | 1997-07-22 | ナショナル ハート アンド ラング インスティチュート | エオタキシン：好酸球走化性サイトカイン |
| US5739103A (en) * | 1993-11-12 | 1998-04-14 | Dana-Farber Cancer Institute | Chemokine N-terminal deletion mutations |
| US5459128A (en) * | 1993-11-12 | 1995-10-17 | Dana-Farber Cancer Institute | Human monocyte chemoattractant protein-1 (MCP-1) derivatives |
| WO1998031794A1 (fr) * | 1997-01-17 | 1998-07-23 | Toa Gosei Co., Ltd. | Polypeptide liant le facteur vegf |
| US6100387A (en) * | 1997-02-28 | 2000-08-08 | Genetics Institute, Inc. | Chimeric polypeptides containing chemokine domains |
| MXPA02001417A (es) * | 1999-08-09 | 2002-08-12 | Lexigen Pharm Corp | Complejos multiples de citosina-anticuerpo. |
| US7332474B2 (en) * | 2001-10-11 | 2008-02-19 | Amgen Inc. | Peptides and related compounds having thrombopoietic activity |
| AU2002337920A1 (en) * | 2001-10-19 | 2003-04-28 | Zymogenetics, Inc. | Dimerized growth factor and materials and methods for producing it |
| AU2003224761A1 (en) * | 2002-03-26 | 2003-10-13 | Centocor, Inc. | Mcp-1 mutant proteins, antibodies, compositions, methods and uses |
| AU2003240765A1 (en) * | 2002-04-10 | 2003-10-20 | Applied Research Systems Ars Holding N.V. | Novel antagonists of mcp proteins |
| WO2007113285A2 (en) * | 2006-03-31 | 2007-10-11 | Biotherapix Molecular Medicines S.L.U. | Mono- and bifunctional molecules with ability to bind to g protein-coupled receptors |
-
2004
- 2004-10-15 AR ARP040103735A patent/AR046594A1/es not_active Application Discontinuation
- 2004-10-18 AU AU2004281552A patent/AU2004281552B2/en not_active Ceased
- 2004-10-18 EA EA200600782A patent/EA009414B1/ru not_active IP Right Cessation
- 2004-10-18 ZA ZA200601900A patent/ZA200601900B/en unknown
- 2004-10-18 CA CA002536082A patent/CA2536082A1/en not_active Abandoned
- 2004-10-18 EP EP04791250A patent/EP1673103A1/en not_active Withdrawn
- 2004-10-18 BR BRPI0415290-5A patent/BRPI0415290A/pt not_active IP Right Cessation
- 2004-10-18 UA UAA200604131A patent/UA91820C2/ru unknown
- 2004-10-18 MX MXPA06003695A patent/MXPA06003695A/es active IP Right Grant
- 2004-10-18 JP JP2006534768A patent/JP2007510403A/ja active Pending
- 2004-10-18 WO PCT/EP2004/052572 patent/WO2005037305A1/en not_active Ceased
- 2004-10-18 US US10/573,625 patent/US7740833B2/en not_active Expired - Fee Related
- 2004-10-18 CN CNA2004800303865A patent/CN1867352A/zh active Pending
- 2004-10-18 KR KR1020067005198A patent/KR20070008510A/ko not_active Ceased
-
2006
- 2006-04-20 IL IL175020A patent/IL175020A0/en unknown
- 2006-05-11 NO NO20062109A patent/NO20062109L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| UA91820C2 (ru) | 2010-09-10 |
| AU2004281552B2 (en) | 2009-10-22 |
| EA009414B1 (ru) | 2007-12-28 |
| IL175020A0 (en) | 2006-08-20 |
| JP2007510403A (ja) | 2007-04-26 |
| BRPI0415290A (pt) | 2006-12-19 |
| US20070280958A1 (en) | 2007-12-06 |
| KR20070008510A (ko) | 2007-01-17 |
| NO20062109L (no) | 2006-05-11 |
| EP1673103A1 (en) | 2006-06-28 |
| CN1867352A (zh) | 2006-11-22 |
| ZA200601900B (en) | 2007-07-25 |
| EA200600782A1 (ru) | 2006-08-25 |
| AU2004281552A1 (en) | 2005-04-28 |
| US7740833B2 (en) | 2010-06-22 |
| WO2005037305A1 (en) | 2005-04-28 |
| AR046594A1 (es) | 2005-12-14 |
| CA2536082A1 (en) | 2005-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lucas et al. | Mapping the lectin-like activity of tumor necrosis factor | |
| MXPA06003695A (es) | Usos terapeuticos de variantes de quimiocinas. | |
| US7425324B2 (en) | Antagonists of MCP proteins | |
| EP1515990B1 (en) | Antagonists of cxcr3-binding cxc chemokines | |
| JP3908165B2 (ja) | 多発性硬化症の治療におけるケモカイン変異体 | |
| AU2002358144B2 (en) | Chemokine mutants acting as chemokine antagonists | |
| AU711573B2 (en) | Short forms of chemokine beta-8 | |
| JPH11243960A (ja) | ヒトｃｃ型ケモカインエオタキシン３ | |
| KR100870296B1 (ko) | 융합 단백질 | |
| EP1673388B1 (en) | Cxcl8 antagonists | |
| EP1020521A1 (en) | Fas Ligand inhibitor ( FLINT ) compositions and uses thereof | |
| JP4001246B2 (ja) | 新規ヒトｃｃ型ケモカインｌａｒｃ | |
| US20030138400A1 (en) | Short forms of chemokine beta-8 | |
| HK1094430A (en) | Therapeutic uses of chemokine variants | |
| JP2006524982A (ja) | 新規ｉｆｎガンマ様ポリペプチド | |
| CA2233367A1 (en) | Short forms of chemokine .beta.-8 | |
| JPWO1998017800A1 (ja) | 新規ヒトｃｃ型ケモカインｌａｒｃ |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GB | Transfer or rights | ||
| FG | Grant or registration | ||
| HC | Change of company name or juridical status |